Annexon (NASDAQ:ANNX - Free Report) had its target price reduced by HC Wainwright from $20.00 to $14.00 in a report issued on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Annexon's Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.50) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.41) EPS and FY2029 earnings at $0.19 EPS.
Separately, Needham & Company LLC reduced their price objective on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday.
View Our Latest Analysis on ANNX
Annexon Price Performance
NASDAQ ANNX traded up $0.20 during trading hours on Wednesday, hitting $2.01. The company's stock had a trading volume of 1,761,522 shares, compared to its average volume of 1,782,376. Annexon has a 12 month low of $1.29 and a 12 month high of $7.85. The company's 50 day simple moving average is $1.91 and its two-hundred day simple moving average is $3.65. The company has a market cap of $220.53 million, a P/E ratio of -1.91 and a beta of 1.24.
Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.07). As a group, research analysts predict that Annexon will post -0.96 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Annexon
Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Annexon during the 4th quarter valued at about $59,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of Annexon during the 4th quarter valued at about $77,000. E Fund Management Co. Ltd. grew its stake in shares of Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock valued at $79,000 after acquiring an additional 4,086 shares during the period. Forefront Analytics LLC grew its stake in shares of Annexon by 56.8% during the 4th quarter. Forefront Analytics LLC now owns 16,433 shares of the company's stock valued at $84,000 after acquiring an additional 5,950 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Annexon during the 4th quarter valued at approximately $98,000.
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
Further Reading
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
